Statin use and risk of contralateral breast cancer: a nationwide cohort study

Abstract

BackgroundStatins have demonstrated antineoplastic effects in breast cancer cell lines, particularly in oestrogen receptor (ER)-negative cell lines. However, epidemiological studies have not supported a preventive effect of statin use against breast cancer. Therefore, we examined the association between statin use and contralateral breast cancer (CBC) risk among women with breast cancer.MethodsWe identified 52,723 women with non-metastatic breast cancer during 1996–2012 from the Danish Breast Cancer Group database. We defined time-varying post-diagnosis statin use as minimum two prescriptions lagged by 1 year. Cox regression analyses were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for CBC associated with statin use.ResultsStatin use was associated with a lower CBC risk (HR = 0.88; 95% CI = 0.73–1.05). The inverse association was strongest for long-term use overall (HR = 0.64; 95% CI = 0.43–0.96), although the HR specifically for long-term consistent use and high-intensity use approached unity. Among ER-negative breast cancer patients, statin use was associated with a CBC risk reduction (HR = 0.67; 95% CI = 0.45–1.00).ConclusionsWe found some indication that statins reduce the risk of CBC. Further evaluations are needed to disentangle the equivocal results for long-term use and to establish if ER-negative breast cancer patients may benefit most from statin use.

Statin use and breast cancer recurrence in postmenopausal women treated with adjuvant aromatase inhibitors: a Danish population-based cohort study

“…Previous studies indicate an association between use of CLM and a reduced risk of breast cancer recurrence (BCR) [ 8 ]. Similarly, long-term post-diagnostic use of statins has been associated with reduced risk of contralateral breast cancer [ 9 ]. Among women with estrogen receptor positive (ER+) breast cancer, statin use seems to have a favorable impact on BCR and mortality when combined with adjuvant endocrine treatment [ 8 , 10 – 12 ].…”

Statin use and risk of liver cancer: Evidence from two population‐based studies

“…With further increases in liver cancer incidence predicted, there is growing interest in identifying modifiable risk factors for liver cancer, especially those that can be targeted with medications, such as aspirin and nonsteroidal antiinflammatory drugs (NSAIDs). Use of statins (or 3‐hydroxy‐3‐methylglutaryl‐coenzyme A reductase inhibitors), commonly used because of their efficacy in preventing cardiovascular morbidity and mortality, has been shown to be inversely related to risk of various cancers …”

“…Use of statins (or 3-hydroxy-3-methylglutarylcoenzyme A reductase inhibitors), commonly used because of their efficacy in preventing cardiovascular morbidity and mortality, has been shown to be inversely related to risk of various cancers. [8][9][10][11] There is increasing evidence from epidemiological studies of an inverse relationship between statin use and the risk of liver cancer. Results from recent systematic reviews and metaanalyses show that, compared to nonusers of statins, individuals using statins have 40-50% lower risk of liver cancer.…”

Statins for the Treatment of Pulmonary Hypertension in Patients with Chronic Obstructive Pulmonary Disease

“…The dose-dependent and time-dependent effects of statins are common to many studies in different populations, making the observed effect more robust ( Liu et al, 2016a ; Liu et al, 2016b ; Langballe et al, 2018 ). In summary, the results suggest that the statins have a protective effect against PH and are effective against PH when patients use them for more than 1 year and at a DDD of more than 10 to 20 per month.…”